Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Insight Molecular Diagnostics Inc.OCX · Entity 6631 | CSO | December 11, 2020 | December 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Insight Molecular Diagnostics Inc.
Report date December 11, 2020 · Filed December 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,477 |
Reported balance
After 2020-12-11 transaction · row 1
1 source rowRow 1 · 2020-12-11 · Grant · Acquired 6,603 · Balance 7,477 F1: The shares of the Issuer's common stock were issued to the Reporting Person for the repayment of deferred compensation in lieu of cash at a price of $2.07 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of the Issuer's common stock were issued to the Reporting Person for the repayment of deferred compensation in lieu of cash at a price of $2.07 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2020 Filed Dec 15, 2020 06:31 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantCommon Stock | 6,603 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-20-023601 · ownership.xml · nonDerivative · entry 1 HESTERBERG LYNDAL K. · CIK 0001689836 · CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,477 F1 · price: The shares of the Issuer's common stock were issued to the Reporting Person for the repayment of deferred compensation in lieu of cash at a price of $2.07 per share. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 19:58 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 350,000 | $0.00 Strike: $3.52 | $0.00 |
DisclosureSEC source: 0001209191-19-020135 · doc4.xml · derivative · entry 1 HESTERBERG LYNDAL K. · CIK 0001689836 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2029-03-13 F1 · derivative.exercise_date: One quarter of the options shall vest upon the completion of one year of continuous service from the date of grant on March 14, 2019 and the balance shall vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, based on continuous service on the applicable vesting date. Read SEC document |
| July 26, 2018 Filed Jul 31, 2018 21:38 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon stock purchase warrants · Derivative | 874 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001493152-18-010762 · ownership.xml · derivative · entry 2 HESTERBERG LYNDAL K. · CIK 0001689836 · Sr VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 874 Underlying: Common stock · 874 shares Expires 2024-02-01 F1 · price: The shares of common stock and the common stock purchase warrants reported in this Form were purchased in "units," with each unit consisting of one share of common stock and one common stock purchase warrant. The purchase price per unit was $2.86. Read SEC document |
| July 26, 2018 Filed Jul 31, 2018 21:38 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon stock, no par value | 874 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-18-010762 · ownership.xml · nonDerivative · entry 1 HESTERBERG LYNDAL K. · CIK 0001689836 · Sr VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 874 F1 · price: The shares of common stock and the common stock purchase warrants reported in this Form were purchased in "units," with each unit consisting of one share of common stock and one common stock purchase warrant. The purchase price per unit was $2.86. Read SEC document |
| May 23, 2018 Filed Jun 4, 2018 20:51 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 150,000 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-18-035400 · doc4.xml · derivative · entry 1 HESTERBERG LYNDAL K. · CIK 0001689836 · Sr VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-05-22 F1 · derivative.exercise_date: These options vest as to one-third of the shares on each of the completion of the clinical utility study for OncoCyte's DetermaVu product candidate, the filing of the Medicare dossier for the Medicare local coverage determination, and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 21:35 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 14,400 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001209191-17-013565 · doc4.xml · derivative · entry 1 HESTERBERG LYNDAL K. · CIK 0001689836 · Sr VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,400 Underlying: Common Stock · 14,400 shares Expires 2027-02-16 F1 · derivative.exercise_date: One quarter of the options shall vest on February 16, 2018, subject to the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.